Celgene seemed like a perfect fit as they would have wanted to shelve Prurisol if it showed efficacy.
My guess is IPIX heading in conjunction with J&J/Pharmacyclics/AbbVie model.
AbbVie is dedicated to R&D. State of the art facility in Cork. Worldwide distribution and a leader within the EU.
Pharmacyclics partnered with J&J and eventually sold to AbbVie for around $20 billion.
Kevetrin can be the P53 modulator to coincide with Imbruvica.
I’m smelling that B-OM FDA minutes holds an easy phase 3. The “company maker”.
Management may have scrapped the partnership with B-OM to go alone. Use the other GI indications to front costs to go at it alone with B-OM and have a blockbuster in the making on IPIX’s terms.
Kevetrin becomes the dark horse. It’s going to get very exciting around here. There is more than just partnership on the horizon... IMO. Your investment will look great soon but extraordinary in the coming years.
Happy Memorial Day to the readers here that are in the states. For the rest, I’m sure it’s business as usual.
News 
Market Data 
Discover 
AI
